A new treatment for brain cancer
Image Source: alternative-cancer.net
Nimotuzumab is a humanised monoclonal antibody that works by binding and disabling the epidermal growth factor receptor. It is a protein that is thought to be a pivotal driver in tumour proliferation. It can be used as monotherapy or in combination with chemotherapy and radiotherapy. This is a mode of treatment for brain cancer that can be used alongside conventional therapies. It has a very low toxicity for a better quality life.
Nimotuzumab as a form of targeted therapy that binds with high specificity is thought to minimally affect normal tissues and have fewer toxic side effects. It is in fact proven safe cancer drug to be used on children with brain tumors in a clinical trial in Germany.
Posted by Ella on October 8th, 2008